Staging of breast cancer in the neoadjuvant setting (Q35638695)

9 August 2017

1 reference

title

Staging of breast cancer in the neoadjuvant setting (English)

1 reference

9 August 2017

10

Kelly K Hunt

1 reference

Ana Maria Gonzalez-Angulo

9 August 2017

4

object named as

Ana M Gonzalez-Angulo

1 reference

9 August 2017

9

Gabriel N Hortobagyi

1 reference

9 August 2017

8

Aman U Buzdar

1 reference

9 August 2017

Jacqueline S Jeruss

1

1 reference

9 August 2017

Elizabeth A Mittendorf

2

1 reference

9 August 2017

Susan L Tucker

3

1 reference

9 August 2017

Thomas A Buchholz

5

1 reference

9 August 2017

Aysegul A Sahin

6

1 reference

9 August 2017

Janice N Cormier

7

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 August 2008

1 reference

9 August 2017

1 reference

9 August 2017

volume

68

1 reference

9 August 2017

issue

16

1 reference

9 August 2017

page(s)

6477-6481

1 reference

A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Gene expression signatures to predict the development of metastasis in breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

A distinct "side population" of cells with high drug efflux capacity in human tumor cells

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Cyclin E and survival in patients with breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Stem cells, cancer, and cancer stem cells

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Specific protection against breast cancers by cyclin D1 ablation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Oncologist communication about emotion during visits with patients with advanced cancer.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Hope and prognostic disclosure

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441792

American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome

25 September 2018

1 reference

12 December 2020

Gene expression profiling in breast cancer

1 reference

12 December 2020

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

1 reference

12 December 2020

Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18

1 reference

12 December 2020

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

12 December 2020

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

12 December 2020

The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer

1 reference

12 December 2020

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

12 December 2020

Genetics and medicine. Putting gene arrays to the test

1 reference

12 December 2020

10.1158/0008-5472.CAN-07-6520

Identifiers

DOI

1 reference

9 August 2017

1 reference

9 August 2017

1 reference